Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30
30 3월 2023 - 10:27AM
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical
company focused on transforming medicines to transform lives,
announced today that it will host a conference call and live
webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a
corporate update and discuss the Company's financial results for
the fourth quarter and full year ended December 31, 2022.
A live audio webcast of the call be accessed by visiting the
investor relations section of the Company’s website,
www.avadel.com. A replay of the webcast will be archived on
Avadel’s website for 90 days following the event. Participants may
register for the conference call here and are advised to do so at
least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plcAvadel
Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company
focused on transforming medicines to transform lives. Our approach
includes applying innovative solutions to the development of
medications that address the challenges patients face with current
treatment options. Our current lead drug candidate, LUMRYZ™, is an
investigational formulation of sodium oxybate leveraging our
proprietary drug delivery technology and designed to be taken once
at bedtime for the treatment of cataplexy or excessive daytime
sleepiness in adults with narcolepsy. For more information, please
visit www.avadel.com.
Investor Contact:Courtney TurianoStern Investor
Relations, Inc.Courtney.Turiano@sternir.com (212) 698-8687
Media Contact:Gabriella GreigReal
Chemistryggreig@realchemistry.com(203) 249-2688
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Avadel Pharmaceuticals (NASDAQ:AVDL)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024